(Q36806124)

16 August 2017

1 reference

title

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure (English)

1 reference

16 August 2017

1 reference

1 reference

Mark C Granberry

1

1 reference

16 August 2017

Jason B Hawkins

series ordinal

2

1 reference

16 August 2017

Amy M Franks

series ordinal

3

1 reference

16 August 2017

language of work or name

1 reference

1 May 2007

1 reference

American Journal of Health-System Pharmacy

16 August 2017

published in

1 reference

16 August 2017

volume

64

1 reference

16 August 2017

issue

9

1 reference

16 August 2017

page(s)

931-936

1 reference

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Role of diabetes in congestive heart failure: the Framingham study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Glycemic control and heart failure among adult patients with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

The prognosis of heart failure in the general population: The Rotterdam Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Insulin resistance and risk of congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Metabolic and additional vascular effects of thiazolidinediones.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Glitazones and heart failure: critical appraisal for the clinician.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Approach to the management of diabetic patients with heart failure: role of thiazolidinediones

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Efficacy of troglitazone on body fat distribution in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Effect of troglitazone on body fat distribution in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060446

31 March 2020

Identifiers

DOI

10.2146/AJHP060446

1 reference

16 August 2017

1 reference